Polaryx Therapeutics (PLYX) Competitors $3.60 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.60 +0.00 (+0.14%) As of 05/22/2026 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PLYX vs. OCGN, NGNE, UPB, FULC, and KMDAShould you buy Polaryx Therapeutics stock or one of its competitors? MarketBeat compares Polaryx Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Polaryx Therapeutics include Ocugen (OCGN), Neurogene (NGNE), Upstream Bio (UPB), Fulcrum Therapeutics (FULC), and Kamada (KMDA). These companies are all part of the "pharmaceutical products" industry. PLYX vs. OCGNPLYX vs. NGNEPLYX vs. UPBPLYX vs. FULCPLYX vs. KMDAHow does Polaryx Therapeutics compare to Ocugen?Polaryx Therapeutics (NASDAQ:PLYX) and Ocugen (NASDAQ:OCGN) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations. Does the media refer more to PLYX or OCGN? In the previous week, Polaryx Therapeutics' average media sentiment score of 0.00 equaled Ocugen'saverage media sentiment score. Company Overall Sentiment Polaryx Therapeutics Neutral Ocugen Neutral Which has preferable valuation & earnings, PLYX or OCGN? Polaryx Therapeutics has higher earnings, but lower revenue than Ocugen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPolaryx TherapeuticsN/AN/AN/AN/AN/AOcugen$4.41M102.86-$67.85M-$0.24N/A Is PLYX or OCGN more profitable? Polaryx Therapeutics has a net margin of 0.00% compared to Ocugen's net margin of -1,192.18%. Polaryx Therapeutics' return on equity of 0.00% beat Ocugen's return on equity.Company Net Margins Return on Equity Return on Assets Polaryx TherapeuticsN/A N/A N/A Ocugen -1,192.18%-127,987.80%-135.48% Do analysts prefer PLYX or OCGN? Polaryx Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 177.78%. Ocugen has a consensus target price of $9.75, suggesting a potential upside of 627.61%. Given Ocugen's stronger consensus rating and higher possible upside, analysts plainly believe Ocugen is more favorable than Polaryx Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polaryx Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Ocugen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Do insiders and institutionals have more ownership in PLYX or OCGN? 10.3% of Ocugen shares are held by institutional investors. 4.0% of Ocugen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryOcugen beats Polaryx Therapeutics on 6 of the 9 factors compared between the two stocks.How does Polaryx Therapeutics compare to Neurogene?Neurogene (NASDAQ:NGNE) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment. Do analysts rate NGNE or PLYX? Neurogene presently has a consensus price target of $74.17, indicating a potential upside of 167.65%. Polaryx Therapeutics has a consensus price target of $10.00, indicating a potential upside of 177.78%. Given Polaryx Therapeutics' higher probable upside, analysts plainly believe Polaryx Therapeutics is more favorable than Neurogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurogene 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86Polaryx Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is NGNE or PLYX more profitable? Polaryx Therapeutics' return on equity of 0.00% beat Neurogene's return on equity.Company Net Margins Return on Equity Return on Assets NeurogeneN/A -37.88% -34.70% Polaryx Therapeutics N/A N/A N/A Do insiders and institutionals have more ownership in NGNE or PLYX? 52.4% of Neurogene shares are owned by institutional investors. 11.7% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has stronger earnings and valuation, NGNE or PLYX? Polaryx Therapeutics has lower revenue, but higher earnings than Neurogene. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurogene$930K470.77-$90.35M-$4.55N/APolaryx TherapeuticsN/AN/AN/AN/AN/A Does the media prefer NGNE or PLYX? In the previous week, Neurogene had 12 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 12 mentions for Neurogene and 0 mentions for Polaryx Therapeutics. Neurogene's average media sentiment score of 0.20 beat Polaryx Therapeutics' score of 0.00 indicating that Neurogene is being referred to more favorably in the media. Company Overall Sentiment Neurogene Neutral Polaryx Therapeutics Neutral SummaryNeurogene beats Polaryx Therapeutics on 8 of the 11 factors compared between the two stocks.How does Polaryx Therapeutics compare to Upstream Bio?Upstream Bio (NASDAQ:UPB) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership. Does the media refer more to UPB or PLYX? In the previous week, Upstream Bio's average media sentiment score of 0.90 beat Polaryx Therapeutics' score of 0.00 indicating that Upstream Bio is being referred to more favorably in the media. Company Overall Sentiment Upstream Bio Positive Polaryx Therapeutics Neutral Which has preferable earnings and valuation, UPB or PLYX? Polaryx Therapeutics has lower revenue, but higher earnings than Upstream Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUpstream Bio$2.85M159.82-$143.44M-$2.91N/APolaryx TherapeuticsN/AN/AN/AN/AN/A Do analysts prefer UPB or PLYX? Upstream Bio presently has a consensus target price of $38.75, suggesting a potential upside of 362.96%. Polaryx Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 177.78%. Given Upstream Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Upstream Bio is more favorable than Polaryx Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upstream Bio 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40Polaryx Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is UPB or PLYX more profitable? Polaryx Therapeutics has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Polaryx Therapeutics' return on equity of 0.00% beat Upstream Bio's return on equity.Company Net Margins Return on Equity Return on Assets Upstream Bio-4,718.96% -43.82% -42.27% Polaryx Therapeutics N/A N/A N/A SummaryUpstream Bio beats Polaryx Therapeutics on 5 of the 8 factors compared between the two stocks.How does Polaryx Therapeutics compare to Fulcrum Therapeutics?Polaryx Therapeutics (NASDAQ:PLYX) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Does the media refer more to PLYX or FULC? In the previous week, Fulcrum Therapeutics had 1 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 1 mentions for Fulcrum Therapeutics and 0 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 0.00 beat Fulcrum Therapeutics' score of -0.50 indicating that Polaryx Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Polaryx Therapeutics Neutral Fulcrum Therapeutics Negative Do insiders and institutionals hold more shares of PLYX or FULC? 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 7.0% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend PLYX or FULC? Polaryx Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 177.78%. Fulcrum Therapeutics has a consensus target price of $19.00, indicating a potential upside of 189.19%. Given Fulcrum Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Fulcrum Therapeutics is more favorable than Polaryx Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polaryx Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Fulcrum Therapeutics 2 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is PLYX or FULC more profitable? Polaryx Therapeutics' return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Polaryx TherapeuticsN/A N/A N/A Fulcrum Therapeutics N/A -27.80%-26.32% Which has higher valuation and earnings, PLYX or FULC? Polaryx Therapeutics has higher earnings, but lower revenue than Fulcrum Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPolaryx TherapeuticsN/AN/AN/AN/AN/AFulcrum Therapeutics$80M5.47-$74.88M-$1.15N/A SummaryFulcrum Therapeutics beats Polaryx Therapeutics on 7 of the 10 factors compared between the two stocks.How does Polaryx Therapeutics compare to Kamada?Polaryx Therapeutics (NASDAQ:PLYX) and Kamada (NASDAQ:KMDA) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment. Is PLYX or KMDA more profitable? Kamada has a net margin of 11.21% compared to Polaryx Therapeutics' net margin of 0.00%. Kamada's return on equity of 7.73% beat Polaryx Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Polaryx TherapeuticsN/A N/A N/A Kamada 11.21%7.73%5.41% Do institutionals and insiders have more ownership in PLYX or KMDA? 20.4% of Kamada shares are owned by institutional investors. 36.1% of Kamada shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts prefer PLYX or KMDA? Polaryx Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 177.78%. Kamada has a consensus target price of $12.00, indicating a potential upside of 53.26%. Given Polaryx Therapeutics' higher probable upside, analysts clearly believe Polaryx Therapeutics is more favorable than Kamada.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polaryx Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Kamada 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to PLYX or KMDA? In the previous week, Kamada had 6 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 6 mentions for Kamada and 0 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 0.00 beat Kamada's score of -0.53 indicating that Polaryx Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Polaryx Therapeutics Neutral Kamada Negative Which has preferable earnings & valuation, PLYX or KMDA? Kamada has higher revenue and earnings than Polaryx Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPolaryx TherapeuticsN/AN/AN/AN/AN/AKamada$180.46M2.50$20.20M$0.3522.37 SummaryKamada beats Polaryx Therapeutics on 9 of the 11 factors compared between the two stocks. Get Polaryx Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLYX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLYX vs. The Competition ExportMetricPolaryx Therapeutics IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$169.31M$2.95B$4.26B$12.34BDividend YieldN/A15.26%5.93%5.28%P/E RatioN/A13.0621.9025.65Price / SalesN/A1,857.06180.5586.28Price / CashN/A27.6455.6856.67Price / BookN/A6.1334.857.14Net IncomeN/A-$42.06M$112.32M$335.98M7 Day Performance30.43%0.99%2.55%3.56%1 Month Performance-25.77%1.57%3.54%2.54%1 Year PerformanceN/A18.73%15.79%35.05% Polaryx Therapeutics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLYXPolaryx TherapeuticsN/A$3.60flat$10.00+177.8%N/A$169.31MN/AN/A11OCGNOcugen1.5844 of 5 stars$1.39-4.8%$9.75+601.4%+44.0%$494.24M$4.41MN/A80NGNENeurogene3.0051 of 5 stars$29.82-4.6%$67.00+124.7%+60.4%$494.12M$930KN/A90Gap DownUPBUpstream Bio2.1213 of 5 stars$9.09+3.4%$38.75+326.3%-8.6%$478.35M$2.85MN/A38Gap DownFULCFulcrum Therapeutics1.7184 of 5 stars$6.69-5.9%$19.00+184.0%+2.0%$473.76M$80MN/A100Gap Up Related Companies and Tools Related Companies OCGN Alternatives NGNE Alternatives UPB Alternatives FULC Alternatives KMDA Alternatives ZURA Alternatives LYEL Alternatives PRTC Alternatives EOLS Alternatives EPRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLYX) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Polaryx Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Polaryx Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
